Adial Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ADIL Nasdaq 2834 www.adial.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration - May 8th, 2025 12:30 pm
EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program - May 8th, 2025 12:02 pm
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds - May 2nd, 2025 3:48 pm
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders - May 1st, 2025 12:30 pm
EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders - May 1st, 2025 12:02 pm
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update - Mar 4th, 2025 1:30 pm
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04 - Feb 25th, 2025 2:00 pm
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder - Feb 25th, 2025 1:30 pm
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies - Feb 19th, 2025 2:00 pm
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - Feb 12th, 2025 2:00 pm
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - Feb 12th, 2025 1:30 pm
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - Jan 29th, 2025 2:00 pm
EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder - Jan 29th, 2025 1:31 pm
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations - Dec 3rd, 2024 1:30 pm
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations - Dec 3rd, 2024 1:00 pm
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know - Nov 25th, 2024 5:00 pm
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - Nov 14th, 2024 1:30 pm
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder - Nov 14th, 2024 1:00 pm
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 13th, 2024 1:30 pm
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - Nov 5th, 2024 1:30 pm